Figure 3.

Effect of BIC, ENZA and APA on the expression of p-AKT, AKT, p-ERK, ERK, p-c-myc and c-myc in LNCaP-WT and LNCaP-STEAP1 knockdown cells. LNCaP cells transfected with siRNA targeting STEAP1 or scramble siRNA. 24 h after tranfection, LNCaP cells were treated with 100 µM of BIC, or 10 µM of ENZA or 10 µM of APA for 24 h. Ratio of phospohorylated forms and total protein of (A) AKT, (B) ERK and (C) c-myc were determined by western blotting after independent normalization with total protein load on gel as represented in (D) together with representative immunoblots. Results are expressed as fold-variation relative to LNCaP-WT (control group). Error bars indicate mean ± standard error of the mean (n≥2). *P<0.05, **P<0.01 and ***P<0.001 vs. the LNCaP-WT condition; ^$P<0.05 and ^$$P<0.01 vs. LNCaP-WT plus respective drug. BIC, bicalutamide; ENZA, enzalutamide; APA, apalutamide; p-, phosphorylated; WT, wild type; STEAP1, six transmembrane epithelial antigen of the prostate 1; siRNA, small interfering RNA.